Brian Fulton, Ph.D. Email & Phone Number

Nashville, TN, US

Nashville, Tennessee, United States

LCMS and GCMS method development for quality control of sterile injectable drug products. Verification, and validation of compendial methods for quality control of raw materials, API’s, and drug products. Particle size analysis of difficult to inspect drug products. Structure identification of API and drug product impurities and degradation products using.

Creation of organization specific GFS and GMP Manuals. Implementation of SOP's and processes. Organization and process specific HACCP Analysis.

MA

Taught undergraduate and graduate level courses in Spectroscopic Analysis (NMR, IR, MS, UV/VIS, Raman), Organic Chemistry, Advanced Organic and Inorganic Synthetic Chemistry, Medicinal Chemistry, Analytical Chemistry, Biochemistry, Pharmaceutical Sciences, and General Chemistry.Chair of Chemistry and Chemical Biology Safety Committee.Full-Time Faculty.

Barnstable, Massachusetts, United States

Organic chemistry lecture and lab

NH

Taught a standard two semester course in Organic Chemistry for Biology majors. Developed laboratory experiments to include the use of analytical instrumentation and methods such as NMR, IR, HPLC, and TLC. Taught a two semester course in Biochemistry for Biology majors emphasizing fundamental principles of biochemistry

MA

Taught lecture and laboratory courses in General Chemistry, Organic Chemistry, Pharmaceutical Chemistry, Heterocyclic Chemistry, and Advanced Experimental Techniques in Organic Chemistry to pharmacy and chemistry major students.

MA

• Medicinal Chemistry of Psychiatric Drugs
• Developed a course in medicinal chemistry allowing students in different programs access to a higher level chemistry course.
• Studied the medicinal chemistry process in developing drugs for the treatment of disorders of mood and behavior where each lecture was centered on a specific psychiatric disorder.
• Examined current theories on the etiology of a disorder and the potential entry points for medication development arising from these theories.
• Discussed current medicinal chemistry research with particular attention on structure-activity-relationships and showing the important relationships between drug structure and pharmacodynamic and pharmacokinetic.
• Emphasized aspects unique to central nervous system drugs such as passage through the blood-brain-barrier.

MA

• Alcohol and Drug Abuse Research CenterDepartment of Medicinal Chemistry
• Design and synthesis of bivalent morphinan ligands specific for the opioid receptors.
• Synthesized linked mixed action mu and kappa receptor agonists ligands to explore the relevance of opioid receptor dimerization to the phenomenological interaction between opioid receptors and antinociception and acute.
• Quantified reaction rates by kinetic analysis of in vitro metabolism of the bivalent ligands by HPLC. This study was designed to explain some interesting structure-activity relationships discovered while conducting in.
• Synthesized analogs of butorphan and butorphanol (a commercially available analgesic) to better define the mode of interaction of the compounds with their binding sites on the mu and kappa receptors.
• Synthesized 2H (deuterium) labeled butophanol analogs

MA

• Design, synthesis, and spectroscopic characterization of yellow, magenta, and cyan xanthene dyes for thermal printing technologies.
• Process development and kilogram production of new xanthene dyes.
• Extensive use of 1H, 13C, 19F NMR, Mass Spectrometry, and UV/VIS spectroscopy

Paris Area, France

• Lead an industrial collaboration on the use of combinatorial chemistry to discover a serine protease stabilization system for use in detergents.
• The goal of the industrial collaboration was to discover weak reversible inhibitors of subtilisin enzymes. End product is for use in concentrated detergents where the protease enzymes are prevented from hydrolyzing.
• Structure guided ligand design, virtual screening, and combinatorial chemistry was used to develop and prepare a library of 1000 compounds. Project manager interfacing with the marketing and technical staff in the.

MA

• Process chemistry Group Leader on the production of building blocks allowing the synthesis of ArQule’s first library of 5000 compounds in 1994.
• Design of library chemistries and the optimization and validation of reaction conditions for use in automated synthesis resulting in the production of over 20,000 Mapping ArrayTM compounds using automated solution.
• Collaborated with the molecular modeling department on the use of aminimides as peptidomimetics.
• Project Leader for first pharmaceutical collaboration with Abbott Laboratories with the responsibility of directing five chemists.
• Developed ArQule’s Directed ArrayTM business model
• Responsible for three research groups as Director of Lead Optimization containing a total of twenty chemists

MA

• Design and synthesis of visible and near–infrared laser absorbing dyes.
• Synthesized new and novel phthalocyanine, organometallic, and squaric acid based dyes
• Examined the incorporation of these dyes into plastics by injection molding and solution casting
• Directed the process chemistry of 10 commercial laser-absorbing dyes that were used in a product line of laser protective eyewear
• Assembled and operated a 5 gallon Pfaulder reactor for production of a dye on the kilogram scale used in welding protective eyewear
• Extensive use of NIR absorption spectroscopy.

MA

• Lead chemist on a SBIR Phase 1 grant on the lead optimization of bone resorption inhibitors based on the benzothiophene core, TNCATM.
• Synthesized heterocyclic compounds based on benzothiophene carboxylic acid, thiophene carboxylic acid, and their bioisoters
• Investigated if new compounds were targeted preferentially to bone or act as prodrugs
• Developed a HPLC method to determine logP values that compared favorably to the traditional shake-flask method.
• Lead optimization of SEPA percutaneous absorption enhancers lead to the percutaneous absorption enhancer, 2–nonyl dioxolane.
• Synthesis of three compounds was optimized and produced and purified on a four liter scale in support of preclinical testing and formulation studies.

Boston, MA

• Investigated bioorganic and biochemical aspects of the mammalian visual cycle.
• Measured the kinetics of retinoid isomerization in liposomes to confirmed that Schiff base formation accelerated the isomerization of 11–cis retinal to all–trans retinal via acid catalysis.
• Discovered and partially isolated a fundamentally important membrane bound retinol isomerase enzyme present in the bovine eye.
• Determined the cellular location of the enzyme by standard cell fractionation procedures.
• Discovered that the isomerase enzyme actually exists in a retinyl ester synthetase/retinol isomerase complex by studying the effects of chemical reagents on enzymatic kinetic activity.
• Extensive use of HPLC, handling radioactive 3H retinoids, biochemical tools

Doctor Of Philosophy (Ph.D.), Organic Chemistry

Developed a tandem Claisen-Diels–Alder reaction for use in synthetic approaches towards linear polycyclic natural products such as.

Bachelor Of Science (Bs), Chemistry, Mathematics

• Studied of transition metal complexes by electron spin resonance spectroscopy • Studied reactivity of sterically hindered Grignard.